‘Fight club’ – Biologics in asthma: RCTs

S46 Tezepelumab reduces mucus plugging in patients with uncontrolled, moderate-to-severe asthma: the phase 2 CASCADE study

Pub Date : 2022-11-01 DOI: 10.1136/thorax-2022-btsabstracts.52 L. Nordenmark, C. Emson, A. Hellqvist, J. Johnston, H. Greberg, JM Griffiths, JD Newell, J. Parnes, G. Colice, C. Brightling

S47 DESTINATION: tezepelumab long-term safety and efficacy versus placebo in patients with severe, uncontrolled asthma

Pub Date : 2022-11-01 DOI: 10.1136/thorax-2022-btsabstracts.53 A. Menzies-Gow, M. Wechsler, C. Brightling, S. Korn, A. Bednarczyk, S. Ponnarambil, G. Almqvist, K. Lawson, S. Caveney, K. Bowen, G. Colice